Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3494

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy of the drug; no safety concern

Conditions

Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

DRUG: Pioglitazone
DRUG: Pioglitazone placebo

Sponsor

Takeda

Collaborators

[object Object]